U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07322016) titled 'A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney Function' on Dec. 19, 2025.
Brief Summary: The primary objective of this study is to evaluate pharmacokinetics of HRS-1301 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Hyperlipidemias
Intervention:
DRUG: HRS-1301 Tablet
HRS-1301 tablet, oral medication.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shandong Suncadia Medicine Co., Ltd.
Disclaimer: Curated by HT Syndicatio...